Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
FBXO3-DT (FBXO3 divergent transcript), also known as LINC02722, is a long non-coding RNA transcript located near the FBXO3 gene locus. There is currently no known evidence that this RNA serves as a drug target, biomarker, or has any characterized molecular or disease function. It should not be confused with FBXO3, which is a protein-coding gene involved in ubiquitin-mediated protein degradation and regulation of inflammation, immunity, cellular apoptosis, and neuropathic pain[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on FBXO3 divergent transcript (FBXO3-DT).